RecruitingHead and Neck CarcinomaAdenoid Cystic CarcinomaLung Cancer
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Eligible age
18–80 yrs
Accepts
All genders
Locations
11 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Sponsor: VM Oncology, LLC
Where it's recruiting
California
Santa Rosa
Connecticut
Hartford
District of Columbia
Washington D.C.
Florida
Fort Lauderdale · Pembroke Pines
New Jersey
Englewood · Florham Park · Morristown
New Mexico
Albuquerque
New York
New York
Ohio
Maumee
Pennsylvania
York
Texas
Houston
Utah
Salt Lake City
Source: ClinicalTrials.gov · NCT03556228 · last updated 2025-12-11